Rennie tablets chewable with menthol flavour

Valsts: Armēnija

Valoda: angļu

Klimata pārmaiņas: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktīvā sastāvdaļa:

calcium carbonate, magnesium carbonate

Pieejams no:

Delpharm Gaillard

ATĶ kods:

առկա չէ (A02AX)

SNN (starptautisko nepatentēto nosaukumu):

calcium carbonate, magnesium carbonate

Deva:

680mg+ 80mg

Zāļu forma:

tablets chewable with menthol flavour

Vienības iepakojumā:

(12/1x12/) and (24/2x12/) in blister

Receptes veids:

OTC

Autorizācija statuss:

Registered

Autorizācija datums:

2018-08-08

Produkta apraksts

Page 1 of 4
Summary of Product Characteristics
Rennie
®
, chewable tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Rennie
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One chewable tablet contains:
Calcium carbonate
680 mg
Magnesium carbonate heavy
80 mg
3.
PHARMACEUTICAL FORM
Chewable tablet
4.
CLINICAL PARTICULARS
_4.1 _
_THERAPEUTIC INDICATIONS _
■
For the relief of heartburn and acid reflux.
_4.2 _
_POSOLOGY AND METHOD OF ADMINISTRATION _
Adults and children over 12 years:
1-2 tablets as a single dose, in case of pane 4 to 8 tablets a day can
be taken. The
tablets are to be chewed or sucked.
In case of severe pains maximum daily dose can be increased for a
short time to
11 tablets per day.
Length of treatment should not exceed 10 days.
_4.3 _
_CONTRAINDICATIONS _
Nephrocalcinosis,
severe
renal
failure
(creatinine
clearance
below
30
ml/min),
hypercalcemia,
hypercalciuria,
hypophosphatemia;
patients
with
rare
hereditary
problems
of
fructose
intolerance,
glucose-galactose
malabsorption
or
sucrase-
isomaltase insufficiency; hypersensitivity to any of the ingredients
of the product;
myasthenia; enterostasis.
_4.4 _
_SPECIAL WARNINGS AND PRECAUTIONS FOR USE _
Do
not
exceed
the stated
dose.
Prolonged use
should
be
avoided.
Length of
treatment should not exceed 10 days. If symptoms persist for more than
10 days or
only partly disappear, further medical advice should be sought.
Caution should generally be exercised in the case of patients with
impaired renal
function. If calcium carbonate and magnesium carbonate products are to
be used in
these patients, plasma calcium, phosphate and magnesium levels should
be regularly
monitored.
None of these Rennie products should be used in cases of
hypercalciuria. Long-term
use
at
high
doses
can
result
in
undesirable
effects
such
as
hypercalcemia,
hypermagnesemia
and
milk-alkali
syndrome,
especially
in
patients
with
renal
insufficiency. The product should not be taken with large amounts of
milk or dairy
products. Prolonged use of the product increases